Analytical Data
-
Gene name
MTNR1C
- Application
-
Alternative Names
Melatonin receptor Mel1c Z2.3k-5
-
Species
Chicken
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P49288
-
Expression Region
Gly293~Leu346
-
Molecular Weight
39kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTNR1C, a melatonin receptor subtype, plays a crucial role in various physiological processes, such as circadian rhythm regulation, sleep-wake cycles, and reproductive functions. As a G protein-coupled receptor (GPCR), MTNR1C mediates the effects of melatonin, a hormone that influences biological rhythms in response to light exposure. The research surrounding MTNR1C recombinant proteins has gained traction due to their potential implications in understanding sleep disorders, mood regulation, and other melatonin-related pathologies. Utilizing recombinant DNA technology, scientists can produce MTNR1C proteins in heterologous systems, allowing for advanced studies of receptor pharmacology, signaling pathways, and structural biology. Investigating MTNR1C through recombinant proteins also provides insight into receptor interactions and offers a platform for drug discovery aimed at targeting sleep-related issues and mood disorders. The availability of these proteins enables high-throughput screening assays and facilitates the identification of novel ligands, contributing to the development of therapeutic agents that can modulate MTNR1C activity. Consequently, understanding the biology of MTNR1C and its recombinant forms holds significant promise for translating findings into clinical applications.
